AFP and hepatocellular carcinoma: Previous studies on prognostic factors for mortality in sorafenib-treated HCC patients have focused on tumor-associated factors, including extrahepatic metastasis, vascular invasion, high alpha-fetoprotein levels, and unfavorable liver function [6,7,8].